Parasympathetic tone and chronic diseases – what does the clinical evidence say today?
I cover the basics of the autonomic nervous system in the article on the autonomic nervous system and vagus stimulation. Home tVNS devices are compared in detail in the tVNS product focus article.
In the video overview: how parasympathetic tone relates to chronic inflammation and what role vagus stimulation may play within a complex treatment package.
Key point
Non-invasive vagus stimulation (tVNS) is an adjunct modality — not a standalone cure for chronic diseases. Current clinical evidence provides moderate-strength support for postural tachycardia syndrome [8], sleep disturbances associated with chronic stress and post-traumatic stress disorder (PTSD), and chronic kidney disease on hemodialysis [6]. Emerging (preliminary) evidence supports use in long COVID [4][5][7], drug-resistant restless legs syndrome [3], and inflammatory bowel diseases (IBD) [1][2]. There is no evidence for tVNS efficacy in oncology or dementia treatment.
How does the vagus nerve connect to chronic inflammation?
According to the 2020 Hilderman & Bruchfeld review [2], the vagus nerve regulates systemic inflammatory responses as part of a so-called cholinergic anti-inflammatory pathway (CAP). This neuro-immune connection increasingly appears in research on many chronic diseases:
The vagus nerve maintains continuous bidirectional communication between the central nervous system and visceral organs via afferent (incoming) and efferent (outgoing) fibers. According to the cholinergic anti-inflammatory pathway [2] model, vagal efferents trigger acetylcholine release in the spleen and other immune organs, which inhibits pro-inflammatory cytokine production (TNF-α, IL-6) by immune cells. A 2022 animal experiment [1] reported that just 1 minute of vagus stimulation significantly reduced the extent of small bowel inflammation in an indomethacin-induced model. Important: animal results have limited direct transferability to humans — human evidence is currently at an encouraging level for IBD.
The most accepted biomarker of sympathetic–parasympathetic balance is heart rate variability (HRV). Persistently low HRV is associated with cardiovascular risk, sleep disorders and psychiatric complaints. A 2023 Agarwal animal study in rats exposed to chronic unpredictable stress showed that tVNS reduced serum stress hormones and inflammatory cytokines while improving ECG parameters. The 2024 Stavrakis human RCT [8] found that in POTS patients a 2-month tVNS protocol reduced postural heart rate increase and improved HRV parameters. Autonomic balance can therefore be measurably modulated; clinical significance varies by indication.
About 80% of the vagus nerve’s afferents carry information from the gastrointestinal tract to the central nervous system. This gut–brain axis explains why vagal tone affects many digestive and psychiatric conditions. The 2022 Caravaca preclinical study [1] found that 1 minute of vagus stimulation significantly reduced indomethacin-induced intestinal inflammation, and the effect was independent of amplitude — so not (only) mediated by the cholinergic pathway. At the human level, SetPoint Medical’s implanted VNS trials for IBD are ongoing; tVNS is currently in investigational phases. Home tVNS DOES NOT replace specialist IBD care.
Where does the clinical evidence stand? – an honest comprehensive picture
Research on vagus stimulation is expanding rapidly, but the quality and quantity of evidence vary considerably across indications. The accordion below categorizes the most frequently mentioned indications into three groups:
The 2024 double-blind, sham-controlled RCT by Stavrakis [8] in 26 POTS patients demonstrated tVNS efficacy: a 2-month protocol of 1 hour daily (20 Hz, 1 mA below the discomfort threshold) significantly reduced the postural heart rate increase (17.6 vs. 31.7 bpm; p=0.01), as well as anti-adrenergic autoantibodies and inflammatory cytokines. Important: POTS is a complex autonomic dysfunction that requires specialist oversight by an autonomic neurologist or internist; tVNS here is also an adjunct modality.
The 2025 Zhang controlled trial [6] in 63 hemodialysis patients tested a daily 1-hour, thrice-weekly, 8-week tVNS protocol. The active group showed significant improvement in dialysis efficiency (single-pool Kt/V: 1.31 vs. 1.25; p=0.02) and dialysis symptoms (DSI: 12.09 vs. 16.26; p=0.004), as well as reduced pain and fatigue scores. The 2020 Hilderman review [2] suggests that modulating the cholinergic anti-inflammatory pathway is a promising approach in chronic kidney disease, where persistent systemic inflammation plays a central role in cardiovascular mortality. tVNS DOES NOT replace dialysis or nephrology care — it should be considered as an adjunct under specialist supervision.
The 2022 Badran pilot RCT [5] studied 13 long COVID patients using a 4-week at-home tVNS protocol (2×1 hour/day). The method was safe and feasible at home; due to small sample size it was underpowered for efficacy but showed a trend toward reduced mental fatigue. The 2024 Zheng pilot study [4] in 24 women with long COVID found that 10 days of at-home tVNS produced significant improvements in cognitive function, anxiety, depression and sleep; fatigue improvement became significant at the 1-month follow-up. The 2023 Linnhoff review [7] lists tVNS as a promising non-invasive neuromodulation option for long COVID–related cognitive fatigue. Important: these are pilot studies; larger randomized, double-blind RCTs are required for definitive confirmation.
The 2023 Hartley pilot study [3] applied weekly 1-hour cymba conchae tVNS over 8 weeks in 15 patients with severe drug-resistant RLS. The method produced symptom reduction in 66% (10/15), lowering the International RLS Scale from 31.9 to 24.6; quality of life improved and anxiety and depression scores decreased. Important: this was a pilot study (small n, no control group); controlled RCTs are needed for confirmation.
Preclinical work by Caravaca [1] and the 2020 Hilderman review [2] indicate that increasing parasympathetic tone may modulate inflammation associated with chronic stress. In humans, vagus stimulation is safe and tolerable, but measuring "stress-reducing" efficacy is methodologically challenging due to placebo effects and confounding factors (sleep, exercise, diet). tVNS alone does not replace a comprehensive stress-management package (exercise, sleep hygiene, diet, psychological support).
The 2022 Caravaca animal study [1] showed that 1 minute of vagus stimulation reduced the extent of intestinal inflammation and inflammatory cytokine levels in an experimental model. SetPoint Medical’s implanted VNS is currently in clinical trials for rheumatoid arthritis and IBD. Human evidence for home tVNS in IBD treatment is currently limited — managing Crohn’s disease and ulcerative colitis is a gastroenterologist’s responsibility, guided by specific medications (5-ASA, corticosteroids, biologics). tVNS could only be an adjunct modality here, alongside specialist consultation.
Important: what CANNOT be claimed?
Vagus stimulation is NOT a proven therapy for oncological diseases, dementia, Alzheimer’s disease or other neurodegenerative conditions. Such claims do not match current clinical evidence. In diabetes, treating insulin resistance, and in atherosclerosis managing cholesterol metabolism are clearly specialist medical tasks — tVNS may be adjunctive but is not a substitute.
Typical tVNS protocol parameters as adjuncts in chronic disease management
Recent clinical trials [3][4][5][6][8] used protocols with differing parameters. Home devices offer built-in, optimized programs:
| Parameter | Range | Note |
|---|---|---|
| Frequency | 20–25 Hz | POTS [8]: 20 Hz; experimental CKD [6]: factory Nurosym setting |
| Intensity | 1 mA below the discomfort threshold | perceptible, but NOT painful |
| Stimulation site | tragus or cymba conchae | RLS [3]: cymba conchae applied |
| Treatment time | 30–60 minutes/session | POTS [8]: 1 hour daily; long COVID [5]: 2×1 hour/day |
| Frequency | 1–2 times daily | RLS [3]: once weekly, longer 8-week program |
| Program period | 4–12 weeks | depends on indication, requires patience |
| Timing | before bedtime or in the morning | not during acute stress |
| Combination | meditation, breathing exercises, yoga | a comprehensive lifestyle approach strengthens the effect |
When is it worth using?
tVNS is most effective when performed in a calm environment, before bedtime or in the morning, at a low activity level. Do not use during acute stress or nervous tension (e.g., during a workplace conflict) — sympathetic activation dominates then and limits stimulation effect. Combining it with meditation, breathing exercises, yoga or calm music can improve the perceived effect.
What can you do to increase parasympathetic tone alongside tVNS?
Increasing vagal tone requires a complex, multimodal approach. tVNS is one building block among many:
- Regular exercise: moderate-intensity aerobic activity (walking, running, cycling, swimming) 150 minutes/week — this is the best-documented lifestyle factor for increasing HRV.
- Breathing exercises: slow, deep breathing (4-7-8, coherent breathing 5–6/min) directly activates the parasympathetic system.
- Sleep hygiene: 7–8 hours of sleep, consistent sleep–wake rhythm, dark/quiet bedroom.
- Stress management: meditation, mindfulness, yoga, nature walks — all have documented HRV-enhancing effects.
- Diet: Mediterranean-type diet, adequate protein and omega-3, avoiding excessive alcohol and caffeine.
- Social connections: strong, supportive social relationships have documented benefits for autonomic balance.
- Cold exposure: short cold showers or facial cold-water exposure can activate vagal tone (the "dive reflex").
tVNS therapy can be applied as an adjunct alongside these lifestyle elements — it does not replace them.
Home tVNS devices
Non-invasive vagus stimulation devices available in the Medimarket portfolio:
- Nurosym – CE-certified transcutaneous auricular vagus stimulator in an ear-clip format. Currently the most widely researched home tVNS device.
- Zenowell Vita – compact auricular tVNS for daily autonomic modulation use.
- Zenowell Luna – auricular tVNS optimized for sleep and evening regeneration programs.
The detailed comparison of the three devices (parameters, target usage) can be found in the tVNS product focus spoke article.
When is tVNS treatment NOT recommended?
General electrotherapy contraindications also apply here (see: electrical treatment contraindications and electrical treatment and implants).
- Pacemaker, ICD, implanted neurostimulator – only with cardiologist/arrhythmologist approval.
- Severe arrhythmia (significant bradycardia, high-grade AV block) – vagus stimulation may further slow heart rate.
- Severe hypotension (low blood pressure) – vagus stimulation may further lower blood pressure.
- Active malignant tumor in the head–neck region – avoid treating over the tumor area.
- Pregnancy – not recommended for general safety reasons.
- Implanted cochlear implant – risk of electrical interference.
- Fresh wound, inflammation or skin infection at the auricular area.
- Acute, unexplained psychiatric or neurological symptoms – specialist evaluation first.
- Epilepsy with poorly controlled medication – individual specialist assessment required.
When treating chronic disease, never stop prescribed medications on your own in favor of tVNS. Any changes must be discussed with your treating physician.
Frequently asked questions about parasympathetic activation and tVNS
No, it does not replace medication. All recent clinical trials [1]–[8] position tVNS as an adjunct modality. Treatment of chronic diseases (POTS, IBD, chronic kidney disease, depression, long COVID, etc.) is specialist care based on specific medications, lifestyle changes and a multidisciplinary approach. Discontinuation, dose reduction or any change of prescribed medication is exclusively the responsibility of the treating physician.
The timeframes in recent clinical trials depend on the indication. In POTS [8] it was 2 months, in hemodialysis [6] 8 weeks, and in RLS [3] 8 weeks were needed for meaningful improvement. Long COVID pilot studies [4][5] showed first changes after 10 days to 4 weeks, with fatigue improvement becoming clearer on further follow-up. In chronic disease, typically at least 4–8 weeks of regular use are required for an adequate evaluation.
No. Current clinical evidence does not support vagus stimulation as a treatment for cancer or dementia. Such claims are marketing-like and not supported by the scientific literature. Oncology treatment is the responsibility of oncologists (surgery, chemotherapy, radiotherapy, immunotherapy); Alzheimer’s and other dementias are managed by neurologists/psychiatrists. Do not accept anyone recommending tVNS as a "cure" for these conditions.
Recent pilot studies [4][5][7] show encouraging signs: the 2024 Zheng study [4] in 24 women found significant improvement in cognitive function, anxiety, depression and sleep after 10 days; fatigue improvement reached significance at 1-month follow-up. But: these are small pilot studies, often without a control group or with limited placebo control. Large randomized, double-blind RCTs are needed for definitive proof. Long COVID is currently managed by multidisciplinary teams (internist, neurologist, physiotherapist, psychologist) — tVNS is an adjunctive experimental option here.
Clinical trials and practical experience suggest tVNS works best in a calm environment, before bedtime or in the morning. The ideal state is sitting or lying in a quiet room, possibly during meditation or deep breathing. Do not use during acute stress, physical activity, or phone/screen use — the sympathetic system dominates then and parasympathetic activation effectiveness decreases.
Generally no — only with cardiologist/arrhythmologist approval. Vagus stimulation can affect heart rate (slowing it); in severe bradycardia, high-grade AV block or sick sinus syndrome this may be dangerous. There is risk of interference with pacemakers, ICDs or other implanted neurostimulators. Detailed considerations are available in the electrical treatment and implants article.
Summary – parasympathetic activation and chronic diseases
What every interested reader should know
- The vagus nerve is the main pathway of the parasympathetic system and part of the cholinergic anti-inflammatory pathway [2] — linking it to chronic inflammation and autonomic dysfunction.
- Moderate evidence: POTS [8] (RCT n=26), hemodialysis [6] (RCT n=63), chronic stress and cardiac dysfunction (animal experiments + review [2]).
- Emerging (pilot) evidence: long COVID [4][5][7], pharmacoresistant RLS [3], IBD (preclinical [1] + ongoing human trials).
- NO evidence: oncology, dementia, standalone treatment of autoimmune diseases — tVNS is NOT a proven therapy in these areas.
- Typical protocol: 20–25 Hz, 30–60 min/day, evening or morning use, 4–12 week program.
- tVNS is an adjunct modality: it does not replace specialist diagnosis, medications or a multidisciplinary treatment package.
- Alongside tVNS, exercise, breathing exercises, sleep hygiene, meditation are documented to increase parasympathetic tone.
- Contraindications (pacemaker, severe bradycardia, low blood pressure, pregnancy, cochlear implant) must be strictly observed.
- Home devices: Nurosym, Zenowell Vita, Zenowell Luna.
Scientific sources (2020+)
References [1]–[8] in the article refer to the following studies (number = ordered list):
- Caravaca AS, Levine YA, Drake A, Eberhardson M, Olofsson PS. Vagus Nerve Stimulation Reduces Indomethacin-Induced Small Bowel Inflammation. Frontiers in Neuroscience. 2022;15:730407. PMID: 35095387.
- Hilderman M, Bruchfeld A. The cholinergic anti-inflammatory pathway in chronic kidney disease – review and vagus nerve stimulation clinical pilot study. Nephrology Dialysis Transplantation. 2020;35(11):1840-1852. PMID: 33151338.
- Hartley S, Bao G, Zagdoun M, Chevallier S, Lofaso F, Leotard A, Azabou E. Noninvasive Vagus Nerve Stimulation: A New Therapeutic Approach for Pharmacoresistant Restless Legs Syndrome. Neuromodulation. 2023;26(3):629-637. PMID: 36400697.
- Zheng ZS, Simonian N, Wang J, Rosario ER. Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in Neurology. 2024;15:1393371. PMID: 38756213.
- Badran BW, Huffman SM, Dancy M, Austelle CW, Bikson M, Kautz SA, George MS. A pilot randomized controlled trial of supervised, at-home, self-administered transcutaneous auricular vagus nerve stimulation (taVNS) to manage long COVID symptoms. Bioelectronic Medicine. 2022;8(1):13. PMID: 36002874.
- Zhang Q, Dou J, Ao H, Guo D, Yang X, Li M. Effect of transcutaneous vagus nerve stimulation in hemodialysis patients: A randomized controlled trial. Therapeutic Apheresis and Dialysis. 2025. PMID: 39754453.
- Linnhoff S, Koehler L, Haghikia A, Zaehle T. The therapeutic potential of non-invasive brain stimulation for the treatment of Long-COVID-related cognitive fatigue. Frontiers in Immunology. 2023;13:935614. PMID: 36700201.
- Stavrakis S, Chakraborty P, Farhat K, Whyte S, Morris L, Abideen Asad ZU, Karfonta B, Anjum J, Matlock HG, Cai X, Yu X. Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial. JACC: Clinical Electrophysiology. 2024;10(2):346-355. PMID: 37999672.
This article is for general informational purposes and does not replace personal medical consultation. The non-invasive tVNS devices presented are CE-certified medical devices; the cited clinical trials used different devices and protocols, and results may vary between individuals. Diagnosis and treatment of chronic diseases are specialist tasks — tVNS is an adjunct modality and does not replace prescribed medications, lifestyle changes or a multidisciplinary treatment package. Contraindications (pacemaker, severe bradycardia, low blood pressure, pregnancy, cochlear implant) must be strictly observed. For new, worsening or unexplained symptoms, consult your treating physician.
